Palisade Bio, Inc. - Common Stock PALI 深 沪
已收盘 08-01 16:00:00 美东时间
1.01
-0.010
-0.98%
华盛通- 最 高1.0796
- 今 开1.01
- 成交量 19.29万股
- 最 低 0.9851
- 昨 收 1.02
- 总市值 484.36万
- 52周最高 4.318
- 市盈率 静 --
- 换手率 4.02%
- 52周最低 0.60
- 委 比 99.00%
- 总股本 479.56万
- 历史最高 18405.00
- 量 比 0.15
- 振 幅 9.26%
- 历史最低 0.60
- 每 手 1
- 风险率 2.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Palisade Bio Secures China Patent For PALI-2108, A Targeted PDE4 Inhibitor For Crohn's Disease And Ulcerative Colitis
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needsInflammatory
07-31 20:46
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Palisade Bio announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor for fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis. The patent, titled “Gut Microbiota-Activated PDE4 Inhibitor Prodrug,” will cover claims on the composition of matter for PALI-2108 in China wi...
07-31 12:45
Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in pre-market...
07-24 17:23
Palisade Bio Raises $3.9M Through Exercise Of 4.3M Warrants At $0.9047/Share; Issues 8.6M New Warrants At Same Price
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
07-24 08:44
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Palisade Bio, Inc. has entered into an agreement with accredited investors to exercise existing warrants to purchase up to 4,318,905 shares of common stock at a reduced price of $0.9047 per share. The gross proceeds from the exercise are expected to be approximately $3.9 million. In exchange for the immediate exercise of the warrants, investors will receive new unregistered warrants (Replacement Warrants) to purchase up to 8,637,810 shares of com...
07-24 00:00
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune, inflammatory, and fibrotic diseases, announced that its CEO, JD Finley, participated in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference. The webcast, which delves into Finley's dedication to the Company and insights into its development programs, is now available on virtualinvestorco.com and the Events page...
07-22 12:45
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review.
07-16 23:54
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
Palisade Bio宣布，Emil Chuang博士加入董事会，他拥有25年的医药经验，擅长炎症性肠病治疗，曾领导多个成功药物开发项目，他对公司针对纤维化克罗恩病和溃疡性结肠炎的项目充满期待。
07-09 12:45
Arrowhead Wraps Enrollment for 3 Key Trials on Fat-Busting Drug, Eyes FDA Decision in November
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions
06-23 19:32
Palisade Bio Reports Improved Quarterly Losses
Palisade Bio, Inc. ( ($PALI) ) has released its Q1 earnings. Here is a breakdow...
06-03 11:53
